Innate Pharma SA (Euronext Paris: IPH – ISIN:
FR0010331421; Nasdaq: IPHA) (“Innate” or the
“Company”) today announced that Sanofi has made
the decision to progress IPH6101/SAR443579 into investigational new
drug (IND)-enabling studies. IPH6101/SAR443579 is a NKp46-based NK
cell engager (NKCE) using Innate’s proprietary multispecific
antibody format (Gauthier et al. Cell 2019).
In the first research program of the collaboration,
IPH6101/SAR443579 has shown anti-tumor activity in pre-clinical
models, including encouraging pharmacokinetic (PK), pharmacodynamic
(PD) and safety data in preliminary non-human primate studies, as
well as positive manufacturability properties, leading to its
selection as a drug candidate for development.
The decision triggered a €7M milestone payment from
Sanofi to Innate. Sanofi will be responsible for all future
development, manufacturing and commercialization of
IPH6101/SAR443579.
This milestone is part of the previously announced
research collaboration with Sanofi, under which the companies
collaborate on the generation and evaluation of up to two
bispecific NKCEs, using technology from Innate and Sanofi’s
proprietary bispecific antibody formats as well as tumor targets.
The companies are also currently working on the second research
program.
“We are very pleased that Sanofi will work to
bring IPH6101/SAR443579 towards the clinic, as it highlights the
potential of engaging NK cells through NKp46, as well as the
robustness of Innate’s proprietary multi-specific antibody format,”
said Pr. Eric Vivier, PhD, Chief Scientific Officer at
Innate Pharma. “We believe IPH6101/SAR443579
is the first NKp46-based NK cell engager to start development,
demonstrating the next wave of scientific innovation at Innate.
This successful validation will also be valuable for our second
ongoing research program with Sanofi, and ultimately, the overall
Innate NK cell engager platform.”
Innate’s multifunctional NKCE technology is
comprised of novel antibody formats that simultaneously target two
activating receptors, NKp46 and CD16, on NK cells as well as a
tumor antigen on cancer cells.
Such trifunctional NKCEs have proven more effective
in pre-clinical models than classical antibodies directed against
the same tumor target, as co-engagement of multiple surface
receptors on NK cells is required for their full activation.
NKCEs may show improved therapeutic window for
cancer treatment as compared to bispecific T lymphocyte-engaging
formats.
About NKp46-based NKCE:
NKp46 is an activating receptor expressed on all NK
cells. It is the most specific marker of human NK cells and plays a
major role in their tumor cell recognition.
Innate’s NKp46 multi-specific NK cell engagers bind
with one arm to an antigen at the surface of tumor cells, and with
another arm to the NKp46 receptor on NK cells. This leads to
activation and specific tumor-killing and cytokine secretion by NK
cells, an immune cell population representing a significant
proportion of all cytotoxic lymphocytes in the body.
About the Innate-Sanofi
agreement:
The Company has a research collaboration and
licensing agreement with Sanofi to apply Innate’s proprietary
technology to the development of innovative multispecific antibody
formats engaging natural killer (NK) cells to kill tumor cells and
secrete cytokines through the activating receptor NKp46.
Under the terms of the licence agreement, Sanofi
will be responsible for the development, manufacturing and
commercialization of products resulting from the research
collaboration. Innate Pharma will be eligible to up to €400m in
development and commercial milestone payments as well as royalties
on net sales.
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies
includes several potentially first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate has been a pioneer in the understanding of
natural killer cell biology and has expanded its expertise in the
tumor microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Based in Marseille, France, Innate Pharma is listed
on Euronext Paris and Nasdaq in the US.Learn more about Innate
Pharma at www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN codeTicker
codeLEI |
FR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information
and risk factors:
This press release contains certain forward-looking
statements, including those within the meaning of the Private
Securities Litigation Reform Act of 1995.The use of certain words,
including “believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts, the Company’s continued
ability to raise capital to fund its development and the overall
impact of the COVID-19 outbreak on the global healthcare system as
well as the Company’s business, financial condition and results of
operations. For an additional discussion of risks and uncertainties
which could cause the company's actual results, financial
condition, performance or achievements to differ from those
contained in the forward-looking statements, please refer to the
Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2019, and subsequent filings
and reports filed with the AMF or SEC, or otherwise made public, by
the Company. This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
InvestorsInnate Pharma Tel.:
+33 (0)4 30 30 30 30investors@innate-pharma.com |
MediaInnate Pharma Tracy Rossin
(Global/US)Tel.: +1 240 801
0076Tracy.Rossin@innate-pharma.comATCG Press Marie
Puvieux (France)Tel.: +33 (0)9 81 87 46
72innate-pharma@atcg-partners.com |
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024